PREPRINT (not peer reviewed)

An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: PsyArXiv
Date: 2025-07-06
Source: PsyArXiv
DOI: 10.31234/osf.io/97cqx_v1
PubMed: Unavailable

Authors

Szigeti B.

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Headache / Migraine Safety Adverse Events Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Feasibility and Tolerability of Psilocybin for Phantom Limb Pain.The journal of pain · 2026-08-07 Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-08-07 A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-07-31 Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01 Balancing safety and access in Oregon’s psilocybin servicesInternational Journal of Drug Policy · 2026-09-01 Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer CareUnknown journal · 2026-08-17 The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-08-14